BRCA1 and metastatic prostate carcinoma: Some of those cohorts specifically include metastatic prostate cancer patients subject to universal testing for somatic variants in BRCA1 and BRCA2. Meta-analyses have attempted to aggregate the results from such cohorts in order to produce pooled estimates, the latest of which by Valsecchi et al. [20].